IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX® technology. Through a differentiated mechanism of action, the DPX® platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers.
For more information, please connect at:
www.imv-inc.com
Company Details
- Employees
- 19
- Founded
- -
- Address
- 130 Eileen Stubbs Ave, Dartmouth,nova Scotia B3b,canada
- Industry
- Biotechnology
- Website
- http://imv-inc.com/
- Keywords
- immunotherapy, DPX Platform, Oncology, Immuno-Oncology, Cancer, Ovarian Cancer, DLBCL, bladder cancer, breast cancer, solid cancer.
- HQ
- Dartmouth, Nova Scotia
Imv Inc. Questions
Imv Inc.'s website is http://imv-inc.com/
Imv Inc.'s LinkedIn profile is https://www.linkedin.com/company/imv-inc
Imv Inc. has
19 employees.
View email and phone details for 19
employees at Imv Inc..
Imv Inc.'s industry is
Biotechnology
Imv Inc.'s top competitors are
Life Sciences Nova Scotia,
Solid State Pharma,
Appili Therapeutics,
Biomedica Diagnostics Inc.,
Biovectra,
Imv Technologies,
Cleardynamic Inc.,
Ir-Scientific,
Medmira Inc.,
Abk Biomedical Inc..
Imv Inc.'s categories are Biotechnology
Imv Inc.'s founding year is 2000
